Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Canadian Science Publishing Country of Publication: Canada NLM ID: 0372712 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1205-7541 (Electronic) Linking ISSN: 00084212 NLM ISO Abbreviation: Can. J. Physiol. Pharmacol. Subsets: MEDLINE
    • Publication Information:
      Publication: 2011- : Ottawa, ON : Canadian Science Publishing
      Original Publication: Ottawa, National Research Council of Canada.
    • Subject Terms:
    • Abstract:
      The objective of the study was to investigate the effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder who received mirtazapine. The study included 109 Russian patients who received mirtazapine at a dose of 30.0 [15.0; 45.0] mg per day. Genotyping of CYP2D6*4 ( 1846G > A , rs3892097 ) was performed using real-time polymerase chain reaction with allele-specific hybridization. The activity of CYP2D6 was evaluated by determining the concentration of endogenous substrate of the enzyme and its urinary metabolite - pinoline to 6-hydroxy-1,2,3,4-tetrahydro-beta-carboline ratio, using high-performance liquid chromatography - mass spectrometry. The statistically significant differences between the scores on the Hamilton Depression Rating Scale (HAMD) in patients with different genotypes were revealed by day 16: ( GG ) 5.0 [3.0; 6.0], ( GA ) 1.5 [1.0; 3.2] ( p < 0.001), and for the The UKU Side Effects Rating Scale (UKU): ( GG ) 6.0 [6.0; 7.0], ( GA ) 8.5 [8.0; 10.0] ( p < 0.001). The calculation of correlation coefficients between the differences in scale scores and metabolic rate showed the presence of statistically significant weak inverse correlation with the efficacy indicator evaluated by HAMD ( r = -0.278, p < 0.05), but not by UKU ( r = 0.274, p > 0.05). This study demonstrated that an increased CYP2D6 activity reduces the efficacy of treatment with mirtazapine.
    • Contributed Indexing:
      Keywords: CYP2D6; mirtazapine; médecine personnalisée; personalized medicine; pharmacogenomics; pharmacogénomique; pinoline
    • Accession Number:
      A051Q2099Q (Mirtazapine)
      EC 1.14.14.1 (Cytochrome P-450 CYP2D6)
    • Publication Date:
      Date Created: 20190518 Date Completed: 20191218 Latest Revision: 20191218
    • Publication Date:
      20201023
    • Accession Number:
      10.1139/cjpp-2019-0177
    • Accession Number:
      31100205
  • Citations
    • ABNT:
      ZASTROZHIN, M. S. et al. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Canadian journal of physiology and pharmacology, [s. l.], v. 97, n. 8, p. 781–785, 2019. DOI 10.1139/cjpp-2019-0177. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=31100205. Acesso em: 3 dez. 2020.
    • AMA:
      Zastrozhin MS, Skryabin VY, Smirnov VV, et al. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Canadian journal of physiology and pharmacology. 2019;97(8):781-785. doi:10.1139/cjpp-2019-0177
    • APA:
      Zastrozhin, M. S., Skryabin, V. Y., Smirnov, V. V., Grishina, E. A., Ryzhikova, K. A., Chumakov, E. M., Bryun, E. A., & Sychev, D. A. (2019). Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Canadian Journal of Physiology and Pharmacology, 97(8), 781–785. https://doi.org/10.1139/cjpp-2019-0177
    • Chicago/Turabian: Author-Date:
      Zastrozhin, M S, V Y Skryabin, V V Smirnov, E A Grishina, K A Ryzhikova, E M Chumakov, E A Bryun, and D A Sychev. 2019. “Effects of CYP2D6 Activity on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders and Comorbid Alcohol Use Disorder.” Canadian Journal of Physiology and Pharmacology 97 (8): 781–85. doi:10.1139/cjpp-2019-0177.
    • Harvard:
      Zastrozhin, M. S. et al. (2019) ‘Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder’, Canadian journal of physiology and pharmacology, 97(8), pp. 781–785. doi: 10.1139/cjpp-2019-0177.
    • Harvard: Australian:
      Zastrozhin, MS, Skryabin, VY, Smirnov, VV, Grishina, EA, Ryzhikova, KA, Chumakov, EM, Bryun, EA & Sychev, DA 2019, ‘Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder’, Canadian journal of physiology and pharmacology, vol. 97, no. 8, pp. 781–785, viewed 3 December 2020, .
    • MLA:
      Zastrozhin, M. S., et al. “Effects of CYP2D6 Activity on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders and Comorbid Alcohol Use Disorder.” Canadian Journal of Physiology and Pharmacology, vol. 97, no. 8, Aug. 2019, pp. 781–785. EBSCOhost, doi:10.1139/cjpp-2019-0177.
    • Chicago/Turabian: Humanities:
      Zastrozhin, M S, V Y Skryabin, V V Smirnov, E A Grishina, K A Ryzhikova, E M Chumakov, E A Bryun, and D A Sychev. “Effects of CYP2D6 Activity on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders and Comorbid Alcohol Use Disorder.” Canadian Journal of Physiology and Pharmacology 97, no. 8 (August 2019): 781–85. doi:10.1139/cjpp-2019-0177.
    • Vancouver/ICMJE:
      Zastrozhin MS, Skryabin VY, Smirnov VV, Grishina EA, Ryzhikova KA, Chumakov EM, et al. Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Canadian journal of physiology and pharmacology [Internet]. 2019 Aug [cited 2020 Dec 3];97(8):781–5. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=31100205